Neurizon Therapeutics Ltd
Research Neurizon Therapeutics Ltd (NUZ) on Bullrun: market cap AUD 63.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNUZ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 63.33M
- Financial periodFY2025
- Net income-AUD 16.59M
- Free cash flow-AUD 14.29M
Valuation Snapshot
latest market cap is AUD 63.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 16.59M | -AUD 14.29M | n/a | -0.03 | AUD 4.16M | n/a | AUD 2.82M |
| FY2024 | n/a | -AUD 7.67M | -AUD 5.17M | n/a | -0.02 | AUD 9.71M | n/a | AUD 10.23M |
| FY2023 | AUD 2.82M | -AUD 6.21M | -AUD 1.60M | 72.1% | -0.02 | AUD 2.71M | AUD 1.05M | AUD 3.89M |
| FY2022 | AUD 3.38M | -AUD 1.71M | -AUD 1.38M | 90.7% | -0.01 | AUD 2.42M | AUD 1.39M | AUD 7.84M |
| FY2021 | AUD 2.14M | n/a | n/a | 89.5% | n/a | n/a | AUD 1.28M | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | AUD 63.33M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neurizon Therapeutics Ltd's market cap?
Neurizon Therapeutics Ltd's market capitalization is AUD 63.33M.
What does Neurizon Therapeutics Ltd do?
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.